| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 0 | 0 | 0 | 880 | 3,940 |
| Sales Growth | unch | unch | -100.00% | -77.67% | -89.10% |
| Net Income | -40,210 | -44,600 | -42,350 | -45,640 | -111,270 |
| Net Income Growth | +9.84% | -5.31% | +7.21% | +58.98% | -55.73% |
Corbus Pharmaceuticals Hldgs Inc (CRBP)
5.20 +0.17 (+3.38%) 04/02/25 [NASDAQ]
5.20 x 4 5.21 x 1
Realtime by (Cboe BZX)
5.20 x 4 5.21 x 1
Realtime 5.20 unch (unch) 16:01 ET
for Wed, Apr 2nd, 2025
Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Fiscal Year End Date: 12/31